Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 12/20 | 0.51 |
| ▸ | FPR3 | P25089 | 11/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25859144 | 0.87 | MKNK1 (0.64) | SMN1; SMN2RAB9AMAPK10FPR2FPR3 | |
| SCHEMBL31271851 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9AMAPK10FPR2FPR3 | |
| SCHEMBL6729 | 0.78 | CCNE1 (0.59) | SMN1; SMN2RAB9AMAPK10CCNE1CDK2 | |
| SCHEMBL10176155 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ALCK | |
| SCHEMBL17631691 | 0.77 | PTPN2 (0.51) | RAB9AFPR2FPR3 | |
| SCHEMBL14476229 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9AMAPK10FPR2FPR3 | |
| SCHEMBL1749806 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPK10CCNE1CDK2 | |
| SCHEMBL17353987 | 0.76 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9AMAPK10CCNE1CDK2 | |
| SCHEMBL24246502 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ACCNE1CDK2CDK5 | |
| SCHEMBL12851970 | 0.76 | RAB9A (0.62) | SMN1; SMN2RAB9AMAPK10CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-06-27 | — | — | US | disclosed |
| CN-117105922-A | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117050032-A | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-110291086-B | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220033392-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-02-03 | — | — | US | disclosed |
| US-11001580-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20190352298-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2019-11-21 | — | — | US | disclosed |
| EP-3555090-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112136-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033392-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | KIT, TNNI3K, CKS1B | SMN1; SMN2 3946/4885RAB9A 1186/4885MAPK10 554/4885 |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | KIT, TNNI3K, CKS1B | SMN1; SMN2 3946/4885RAB9A 1186/4885MAPK10 554/4885 |
| US-11001580-B2 | Aminothiazole compounds as c-Kit inhibitors | KIT, TNNI3K, CKS1B | SMN1; SMN2 4072/4885RAB9A 1407/4885MAPK10 586/4885 |
| US-20190352298-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | KIT, TNNI3K, CKS1B | SMN1; SMN2 4072/4885RAB9A 1407/4885MAPK10 586/4885 |
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | KIT, TNNI3K, CKS1B | SMN1; SMN2 3946/4885RAB9A 1186/4885MAPK10 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.